Letters to the Editor

Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent

Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Jacksonville, FL
Division of Hematology, Mayo Clinic, Jacksonville, FL
Division of Hematology, Mayo Clinic, Jacksonville, FL
Division of Hematology, Mayo Clinic, Scottsdale, AZ
Division of Hematology, Mayo Clinic, Rochester, MN
Division of Hematology, Mayo Clinic, Rochester, MN
Haematologica Early view Mar 28, 2024 https://doi.org/10.3324/haematol.2024.284962